Phase 3 Start
NGEN: Phase3_Start: A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)
September 23, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 23, 2026
- Company
- NERVGEN PHARMA CORP. (NGEN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Start
Phase3_Start: A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)
- Company
- NERVGEN PHARMA CORP. (NGEN)